Evidence map›Paper›PMID 39273357›Full record

ArticleInternational journal of molecular sciences2024

Significance of Fibrillin-1, Filamin A, MMP2 and SOX9 in Mitral Valve Pathology.

Carmen Elena Opris, Horatiu Suciu, Ioan Jung, Sanziana Flamand, Marius Mihai Harpa, Cosmin Ioan Opris, Cristian Popa, Zsolt Kovacs, Simona Gurzu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Mechanisms of mitral valve development and disease.Frontiers in cardiovascular medicine · 2026
    Review
  4. Review
  5. Article
  6. The role of the cytoskeleton in fibrotic diseases.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carmen Elena OprisDepartment of Adult and Children Cardiovascular Recovery, Emergency Institute for Cardio-Vascular Diseases and Transplantation, 540139 Targu Mures, Romania.
Horatiu SuciuDepartment of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
Ioan JungDepartment of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
Sanziana FlamandDepartment of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
Marius Mihai HarpaDepartment of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
Cosmin Ioan OprisDepartment of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
Cristian PopaFaculty of European Studies, Babes-Bolyai University, 400006 Cluj-Napoca, Romania.
Zsolt KovacsDepartment of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, 540139 Targu Mures, Romania.
Simona GurzuDepartment of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.ORCID 0000-0003-3968-5118

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic factors play a significant role in the pathogenesis of mitral valve diseases, including mitral valve prolapse (MVP) and mitral valve regurgitation. Genes like Fibrillin-1 (FBN1), Filamin A (FLNA), matrix metalloproteinase 2 (MMP2), and SRY-box transcription factor 9 (SOX9) are known to influence mitral valve pathology but knowledge of the exact mechanism is far from clear. Data regarding serum parameters, transesophageal echocardiography, and genetic and histopathologic parameters were investigated in 54 patients who underwent cardiovascular surgery for mitral valve regurgitation. The possible association between Fibrillin-1, Filamin A, MMP2, and SOX9 gene expressions was checked in relationship with the parameters of systemic inflammatory response. The mRNA expression levels (RQ-relative quantification) were categorized into three distinct groups: low (RQ < 1), medium/normal (RQ = 1-2), and high (RQ > 2). Severe fibrosis of the mitral valve was reflected by high expression of FBN1 and low expression of MMP2 (

Indexed as

Fibrillin-1FilaminsMatrix Metalloproteinase 2Mitral ValveSOX9 Transcription FactorAdipokinesAgedFemaleHumansMaleMiddle AgedMitral Valve InsufficiencyMitral Valve ProlapseAdipokinesFBN1 protein, humanFibrillin-1FilaminsFLNA protein, humanMatrix Metalloproteinase 2MMP2 protein, humanSOX9 protein, humanSOX9 Transcription FactorFibrillin 1 (FBN1)Filamin A (FLNA)matrix metalloproteinase 2 (MMP2)mitral valveSRY-box transcription factor 9 (SOX9)

Identifiers

PMID39273357
PMCPMC11394784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.